Sen. Bernie Sanders, a longtime pharma watchdog, says he's rolling out legislation to stall drug price hikes. The presidential candidate's proposals include some previously failed measures--including Medicare price negotiations--but they come at a time when public debate about the rising cost of meds has reached a fever pitch.
NovoCure has filed for an IPO to raise up to $300 million on the strength of a potential FDA approval for its Optune device in combination with chemotherapy for patients with newly diagnosed glioblastoma.
Novartis' melanoma duo Tafinlar and Mekinist scored a priority stateside review in July along with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Now the EU has given its final signoff on the combo for patients with a deadly form of the disease.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
Alexion Pharmaceuticals is no longer a one-product company, winning tandem European approvals for two rare disease drugs it hopes will mimic the success of Soliris, the world's most expensive treatment.
Singapore has gathered pace as a place for companies in Asia to source services related to biologic clinical and manufacturing with recent additions in the city-state highlighting niches in a growing market.
Facing an acute shortage of human albumin, the medicines regulator in India's Maharashtra state has written to all blood banks instructing them to provide plasma to the company that produces the most of the product in the state, Reliance LIfe Sciences, in a step that along with imports may ease the situation.
Titan Pharmaceuticals announced that it has resubmitted its application for FDA approval of its subdermal implant for the delivery of buprenorphine/naloxone as a maintenance treatment for opioid addiction. The move follows a surprise rejection in 2013.
Kim Kardashian knows a thing or two about cleaning up messes on social media. Amid the festivities at this past weekend's MTV Video Music Awards, the celebutante put out a corrected social media post for Canadian pharma Duchesnay's morning sickness med, Diclegis, weeks after the FDA came down on the company for violating its branding rules and demanded that it fix the problem.
Over the past two years the reputation of the IT department at the FDA has changed rapidly. Once best known for burning through CIOs and receiving slapdowns from the congressional watchdog, the FDA is now garnering plaudits for its embrace of agile and open development. This new way of thinking is central to--and to an extent responsible for--the recently unveiled precisionFDA initiative.